Plasma amyloid-β biomarkers are associated with Alzheimer's disease comorbidity in Lewy body disease

Moeko Noguchi-Shinohara; Hidetomo Murakami; Yasuhiro Sakashita; Yukiko Mori; Junji Komatsu; Daiki Muramatsu; Sadao Hikishima; Kenjiro Ono

doi:10.1016/j.parkreldis.2023.105445

Plasma amyloid-β biomarkers are associated with Alzheimer's disease comorbidity in Lewy body disease

Parkinsonism Relat Disord. 2023 Jun:111:105445. doi: 10.1016/j.parkreldis.2023.105445. Epub 2023 May 13.

Authors

Moeko Noguchi-Shinohara¹, Hidetomo Murakami², Yasuhiro Sakashita¹, Yukiko Mori², Junji Komatsu³, Daiki Muramatsu¹, Sadao Hikishima¹, Kenjiro Ono⁴

Affiliations

¹ Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
² Department of Neurology, School of Medicine, Showa University, Tokyo, Japan.
³ Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan; Department of Preemptive Medicine for Dementia, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
⁴ Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. Electronic address: onoken@med.kanazawa-u.ac.jp.

PMID: 37201326
DOI: 10.1016/j.parkreldis.2023.105445

Abstract

No blood biomarkers which can identify Alzheimer's disease pathology in Lewy body disease (LBD) have ever been established. We showed that the plasma amyloid-β (Aβ) _1-42/Aβ_1-40 ratio was significantly decreased in patients with Aβ+ LBD compared with those with Aβ- LBD and it might be a useful biomarker.

Keywords: Alzheimer pathology; Lewy body disease; Plasma amyloid-β.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Alzheimer Disease* / pathology
Amyloid beta-Peptides
Biomarkers
Comorbidity
Humans
Lewy Body Disease* / pathology
tau Proteins

Substances

tau Proteins
Amyloid beta-Peptides
Biomarkers